Flexus Biosciences turned heads around the industry when Bristol-Myers Squibb ($BMY) signed a $1.25 billion deal to buy the fledgling biotech in February, but the company's founders aren't resting on their laurels, turning around with immediate plans for a new startup. The acquisition included terms that allowed Flexus' brain trust to spin out cancer candidates into new companies, and, as Chemical & Engineering News reports, founders Terry Rosen and Juan Jaen are wasting no time with that process, beginning an effort they hope can churn out one new project each year. More